Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have received an average rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $41.00.

Several equities analysts recently commented on the company. Zacks Research raised Assembly Biosciences to a “hold” rating in a research report on Tuesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, October 8th. Guggenheim boosted their price objective on shares of Assembly Biosciences from $31.00 to $39.00 and gave the stock a “buy” rating in a report on Monday, September 8th. Citigroup initiated coverage on shares of Assembly Biosciences in a research report on Wednesday, September 24th. They issued an “outperform” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research report on Tuesday, October 14th.

Hedge Funds Weigh In On Assembly Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in shares of Assembly Biosciences by 6,382.7% in the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 3,319 shares during the last quarter. American Century Companies Inc. acquired a new position in Assembly Biosciences during the 1st quarter worth $113,000. Acadian Asset Management LLC increased its position in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 6,823 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Assembly Biosciences in the 3rd quarter worth about $282,000. Finally, Palumbo Wealth Management LLC raised its stake in shares of Assembly Biosciences by 3.8% in the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 681 shares in the last quarter. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Price Performance

Assembly Biosciences stock opened at $35.01 on Monday. Assembly Biosciences has a 12 month low of $7.75 and a 12 month high of $39.71. The company has a market cap of $553.86 million, a price-to-earnings ratio of -7.31 and a beta of 1.14. The stock’s 50-day moving average is $31.31 and its 200-day moving average is $24.03.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.22). The business had revenue of $10.79 million for the quarter, compared to analyst estimates of $7.46 million. Assembly Biosciences had a negative return on equity of 59.01% and a negative net margin of 103.65%. Research analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current year.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.